GLP-2T prices

FROM PEPTIDES CALCULATOR

About Tirzepatide

Source profile reviewed 2026-10-01 · Imported 2026-10-22. Read the full compound profile

Tirzepatide (LY3298176) is a once-weekly injectable peptide that activates both the GIP and GLP-1 receptors, a 39-amino-acid analog with a C20 fatty diacid side chain that binds albumin and gives it a half-life of 5 to 6 days. The FDA approved it in 2022 as Mounjaro for type 2 diabetes, then as Zepbound for chronic weight management and for moderate to severe obstructive sleep apnea in adults with obesity; the 2026 Mounjaro label also covers children from age 10. In the phase 3 program it lowered HbA1c by about 2 percentage points and beat semaglutide 1 mg in SURPASS-2, produced 20.9% mean weight loss at 72 weeks on 15 mg in SURMOUNT-1, and out-performed semaglutide 2.4 mg head to head in SURMOUNT-5. Both labels carry a boxed warning for thyroid C-cell tumors seen in rodents, and compounded or grey-market vials sold at concentrations from 5 to 20 mg/mL account for most of the dosing confusion documented online.

Formula

C225 H348 N48 O68

Molar mass

4,813 g/mol

Amino acids

39

Research evidence described in the source

Limitations noted in the source

• The 2.5 mg initiation dose is not a maintenance dose.
• Risk, contraindication, and interaction information must come from current regulated labeling.
• A calculator preset is a recorded research convention, not a recommendation or evidence of clinical benefit.
• Identity, purity, sterility, and stability can vary substantially outside regulated manufacturing.

Background is reproduced from Peptides Calculator with attribution. The source describes compound-level research. It does not evaluate the identity, quality or suitability of a listed supplier’s product or batch.